Chicago -- The nation's leading biomedical researchers will present breakthrough
therapies and technologies in liver disease November 8 through November 10 at
the 49th Annual Meeting of the American Association for the Study of Liver
Diseases (AASLD), the leading medical organization for liver research.
AASLD encourages the media to attend the more than 500 presentations covering
liver-related diseases featuring never-before published findings on:
- Promising new combination therapies for Hepatitis C & B
- African Americans' dangerously low response rate to Hepatitis C therapies
- The crushing burden of increasing cases of Hepatitis C virus on the U.S.
healthcare system
- Advances in gene therapy technologies
A press room will be available for media representatives in the Sheraton Chicago
Hotel,
Parlor D, on Sunday, November 8, from noon to 5 p.m. and Monday, November 9,
through Tuesday, November 10, 9 a.m. to 5 p.m.
Further information on the meeting, including news releases and abstract
highlight summaries, will be distributed to the media and are also available
upon request.
'"/>
Contact: kirk Monroe
kirkmonroe@aol.com
202-789-2892
American Association For The Study of Liver Diseases
4-Nov-1998
Page: 1 Related biology news :1.
Nations plant database falling behind, survey shows2.
ASM Calls For Focus On Microbial Pollution Of Nations Water Supply3.
Carnegie Mellon Researchers Develop Nations First Robotic Tour Guide For The
Dinosaur Hall At Pittsburghs Carnegie Museum Of Natural History4.
Research Aims At Nations First Smart Ground Water Regulations5.
Leading scientists design new framework for biodiversity conservation6.
Leading science, higher-education and engineering groups urge six improvements to U.S. visa quagmire7.
Leading experts in field of gene therapy to meet in Minneapolis8.
Leading U.S. gun manufacturer joins NJIT to develop personalized handgun9.
Leading bacterial pathogen is sequenced10.
Leading cloning experts challenge Clonaid to prove claim11.
Leading cancer research organization urges FDA to speed approval of drugs for precancers